If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Quinolone-Based Treatment Regimen Safer Than Rifampicin for Treating Tuberculosis in Renal Transplant Recipients: Presented at ATC By Cheryl Lathrop BOSTON -- June 3, 2009 -- A quinolone-based treatment regimen is safer than rifampicin for treating tuberculosis in renal transplant recipients, according to a study presented here at the 2009 American Transplant Congress (ATC). Youn Joo Jeon, MD, College of Medicine, The Catholic University of Korea, Seoul, Korea, and colleagues retrospectively analysed 1,928 renal transplant recipients who underwent transplantation at 2 hospitals in Seoul from March 1969 to April 2009, of which 109 went on to develop tuberculosis. Results were presented on June 2. Of these 109 patients, 91 took rifampicin and 18 took quinolones. The patients’ average age was 43 years; two-thirds were men and one-third were women. The incidence of acute rejection was 4 times higher in the rifampicin group with 24.2% (22/91) of patients developing acute rejection versus 5.6% (1/18) in the quinolone group (P = .049). In addition, the cyclosporine levels were more stable in the quinolone group during treatment ranging from 106.7 to 125.8 ng/mL, while the rifampicin group ranged from 87.6 to 145.2 ng/mL. Of note, when acute rejection occurred in the rifampicin group, converting from rifampicin to a quinolone decreased the graft failure rate (P = .030) and showed better graft survival (P = .006). Of the 22 rejections in the rifampicin group, the 14 patients that stayed on rifampicin had 8 failures (57.1%) and the 8 patients that converted from rifampicin to quinolones had only 1 failure (12.5%). [Presentation title: Quinolone-Based Regimen Is Safe and Effective in Treatment of Tuberculosis in Renal Transplant Recipients. Abstract 1616]
|
